Advice
Following a full submission
Ibritumomab tiuxetan (Zevalin) is not recommended for use within NHS Scotland for the preparation of a radiopharmaceutical incorporating Yttrium 90 [90Y] for the treatment of adult patients with rituximab-relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma.
No economic information was submitted to allow an assessment of its cost effectiveness.
Download detailed advice48KB (PDF)
Medicine details
- Medicine name:
- Ibritumomab tiuxetan (Zevalin®)
- SMC ID:
- 171/05
- Indication:
- Rituximab-relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma.
- Pharmaceutical company
- Schering Health Care Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 09 May 2005